Physician profile
Randee E Lipman
NPI 1598701922
$3,908.28
in general payments reported to CMS, 2019-2025
30 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $191 · 2021: $637 · 2022: $274 · 2023: $450 · 2024: $887 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $447.05 | 2020-2025 | Aveir, Cardiomems, Assurity |
| Novartis Pharmaceuticals Corporation | $407.90 | 2019-2025 | |
| Amgen INC. | $389.22 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $295.47 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $279.97 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $259.41 | 2022-2025 | Camzyos, Eliquis, Empliciti |
| Medtronic, INC. | $232.74 | 2021-2025 | Linq II, Micra |
| Sanofi-Aventis U.S. LLC | $183.69 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $177.69 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $172.17 | 2019-2023 | Xarelto |
| Cvrx, INC. | $138.69 | 2021-2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.60 | 2022-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $105.53 | 2019-2025 | Evkeeza |
| Philips North America LLC | $86.77 | 2024 | (5091) Amb Mon & Diag Und, (Ck4) Mcot |
| Pfizer INC. | $70.16 | 2019-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $67.83 | 2019-2021 | |
| Lundbeck LLC | $67.00 | 2019-2020 | |
| Biotronik INC. | $62.95 | 2020-2021 | |
| Inari Medical, INC. | $49.73 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kiniksa Pharmaceuticals, Ltd. | $39.10 | 2023 | Arcalyst |
| Boston Scientific Corporation | $36.98 | 2021-2022 | |
| Penumbra, INC. | $35.74 | 2025 | Penumbra System |
| Bayer Healthcare Pharmaceuticals INC. | $32.70 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $31.51 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $26.93 | 2024-2025 | Opsumit, Uptravi |
| Amryt Pharma Holdings Ltd | $26.24 | 2020 | |
| Shockwave Medical, INC | $25.69 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $23.12 | 2023 | Inpefa |
| Arbor Pharmaceuticals, INC. | $16.21 | 2021 | |
| Amarin Pharma, INC. | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randee Lipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.